Restructuring and impairment charges consisted of the following for the year ended December 31, 2022 (in thousands):

Impairment of property and equipment	$	1,548
Inventory obsolescence		1,000
Severance expense		910
Prepaid expenses		395
Contract termination fees		319
Total restructuring and impairment charges	$	4,172

The Company’s RIF was completed in September 2022 and impacted approximately 85% of its full-time employees, resulting in one-time severance payments totaling approximately $0.9 million. In addition, the Company discontinued enrollment of patients in its clinical trial, ceased engineering and manufacturing activities, sold or disposed of substantially all of its property and equipment, inventories and research and development supplies, resulting in impairment and inventory obsolescence charges and the write-off of prepaid research and development supplies totaling approximately $2.9 million during the year ended December 31, 2022.